ZyVersa Therapeutics Inc.
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glome… Read more
ZyVersa Therapeutics Inc. (ZVSA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 119.987x
Based on the latest financial reports, ZyVersa Therapeutics Inc. (ZVSA) has a cash flow conversion efficiency ratio of 119.987x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.41 Billion) by net assets ($-11.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ZyVersa Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how ZyVersa Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ZyVersa Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ZyVersa Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pambili Natural Resources Corporation
V:PNN
|
-0.026x |
|
Bertam Alliance Bhd
KLSE:9814
|
-0.016x |
|
Adeunis
PA:ALARF
|
-3.682x |
|
Psyched Wellness Ltd
OTCQB:PSYCF
|
-0.248x |
|
Pinstripes Holdings Inc
NYSE:PNST
|
0.049x |
|
Liquid Meta Capital Holdings Ltd.
PINK:LIQQF
|
-0.007x |
|
Invicta
JSE:IVT
|
0.052x |
|
PRODWARE INH. EO-65
F:9S6
|
N/A |
Annual Cash Flow Conversion Efficiency for ZyVersa Therapeutics Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of ZyVersa Therapeutics Inc. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.52 Million | $-7.56 Million | -0.888x | -12.72% |
| 2023-12-31 | $11.07 Million | $-8.72 Million | -0.787x | -1510.74% |
| 2022-12-31 | $99.99 Million | $-4.89 Million | -0.049x | -112.04% |
| 2021-12-31 | $-12.50 Million | $-5.08 Million | 0.406x | -31.99% |
| 2020-12-31 | $-8.56 Million | $-5.11 Million | 0.597x | -- |